Benzinga | Jan 19, 2022 08:24AM EST

Goldman Sachs Upgrades Arrowhead Pharmaceuticals to Buy

Goldman Sachs analyst Madhu Kumar upgrades Arrowhead Pharmaceuticals (NASDAQ:ARWR) from Neutral to Buy.